Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q2 EPS of ($1.06), $0.32 worse than the analyst estimate of ($0.74). Revenue for the quarter came in at $176 million versus the consensus estimate of $166.03 million.

FY 2026 Outlook:-

Revenue between $680 million to $700 million vs consensus $678 million.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.